# Cullinan Therapeutics Inc. (CGEM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $22.09, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cullinan Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -53.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: 24.8%**. Each dollar of assets produces 24.8% of profit.

## Financial health
- **Current ratio: 10.25** (quick 10.25). Current assets cover the next year's liabilities 10.25 times.

## Dividends
- **Dividend: none**. Cullinan Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Cullinan Therapeutics Inc.; the consensus is strong_buy, with an average price target of $32.36 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 219.7%** (YTD 113.4%, 3-mo 63.5%). The shares are up 219.7% over twelve months including dividends.
- **From 52-week high: -4.7%** (288.9% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 1.36** (volatility 79%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CGEM · Page: https://foliofundamentals.com/stocks/cgem

Not investment advice.